<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">von Birgelen, Clemens</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Third-Generation ZES Matches EES in Efficacy and Safety, without Evidence of Longitudinal Deformation in an All-Comer Population</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents 1-year data from the Durable Polymer-Based Stent Challenge of Promus Element Versus Resolute Integrity in an All Comers Population [DUTCH PEERS (TWENTE II); von Birgelen C et al. Lancet 2013 (epublished ahead of print)] study. The results demonstrated comparable clinical outcomes with zotarolimus-eluting stents and everolimus-eluting stents (EES); both are third-generation, permanent, polymer-based, drug-eluting stents. There was no significant difference in efficacy and safety between the two stents, and longitudinal stent deformation was only seen in the EES group.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>